viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals posts strong year-over-year increase in 2Q revenue

For the three months ended September 30, total revenue was C$16.4 million, compared to revenue of C$3.4 million in the prior-year quarter

Medexus Pharmaceuticals Inc - Medexus Pharmaceuticals Inc fiscal second-quarter shows strong year-over-year increase in revenue
Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics

Medexus Pharmaceuticals Inc (CVE:KMDP) (OTCMKTS:PDDPF) has released fiscal second-quarter results showing a strong year-over-year increase in revenue. 

For the three months ended September 30, the Montreal-based drugmaker said total revenue was C$16.4 million, compared to revenue of C$3.4 million in the prior-year quarter. 

“This improvement reflects continued unit sales growth, as well as the increased scale of the company as a result of the acquisitions completed in October 2018,” said CEO Ken d’Entremont in a statement issued Friday.

READ: Medexus Pharmaceuticals wins priority review status from Health Canada for brain tumor aid Gliolan

Medexus is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication.

“Specifically, Metoject unit market demand increased 115%, Rasuvo unit market demand increased 15%, and Rupall unit market demand increased 66% over the same period last year,” d’Entremont added.

Medexus reported other quarterly highlights:

  • Gross profit of C$9.6 million, compared to C$1.9 million in the year-ago quarter;
  • Gross margin was 58.6%, compared to 53.8% in 2Q 2019;
  • Adjusted EBITDA  was C$0.5 million, compared to C$0.5 million for the prior-year quarter;
  • Net income was C$0.7 million, compared to a net loss of C$3.6 million in 2Q 2019;
  • Finished the quarter with cash and cash equivalents of C$25.4 million

“Looking ahead, we have built a highly scalable organization and look forward to leveraging our North American sales force by licensing additional products and through accretive acquisitions,” said d’Entremont.

"As a result, we remain encouraged by the outlook for fiscal 2020, as illustrated by the fact we have repurchased over 600,000 shares year-to-date under the company’s normal course issuer bid. At the same time, we have maintained a solid balance sheet with C$25.4 million of cash and cash equivalents, as well as a working capital surplus of approximately C$29.4 million as of September 30, 2019.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Medexus Pharmaceuticals Inc

Price: 2.81 CAD

Market: TSX-V
Market Cap: $39.5 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...



Full interview: Medexus Expands US assets by acquiring Aptevo Bio Therapeutics

Medexus Pharmaceuticals (CVE: MDP-OTCQB: PDDPF) CEO Ken d’Entremont joined Proactive's Steve Darling in Toronto with news the company has acquired Aptevo BioTherapeutics LLC, which owns the worldwide rights to the commercial hematology asset, IXINITY, for up-front cash consideration of...

on 4/3/20

2 min read